# IMforte (NCT05091567)

> A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05091567
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Small-Cell Lung Cancer
- Interventions: Atezolizumab; Lurbinectedin; Carboplatin; Etoposide
- Enrollment: 660
- Primary outcome: Randomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS)
- Primary outcome: Randomized Phase: Overall Survival (OS)

## Commentary we found

- X threads: 127
- YouTube: 34
- Podcasts: 24
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=imforte-nct05091567

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05091567", "email": "<work email>"}; the inbox owner confirms by the emailed link.